MMPOWER-3 (phase 3, double-blind, placebo-controlled)
- Population
- 218 adults with genetically confirmed primary mitochondrial myopathy (109 elamipretide, 109 placebo)
- Comparison
- Elamipretide 40 mg once daily vs placebo, subcutaneous
- Comparator
- Placebo, subcutaneous once daily for 24 weeks
- Endpoint
- Co-primary: change from baseline in six-minute walk distance, and in the PMMSA total fatigue score
- Time point
- Week 24
- Result
- Primary endpoints not met. Difference in least-squares mean change, elamipretide minus placebo: six-minute walk distance -3.2 m (p=0.69); total fatigue score -0.07 (p=0.37).
- Uncertainty
- Six-minute walk distance difference: 95% CI -18.7 to 12.3 m. Total fatigue score difference: 95% CI -0.10 to 0.26 as printed in the abstract.
- Source
- PMID 37268435, doi:10.1212/WNL.0000000000207402, registry NCT03323749
- Where each number sits (partly matched)
- Neurology 2023 abstract (PubMed 37268435): participants, endpoints and both differences. ClinicalTrials.gov NCT03323749 results, primary outcome measure 1 (six-minute walk): week 24 mean change 15.330 m (SD 61.486, n=109) elamipretide and 17.386 m (SD 51.696, n=109) placebo. The registry reports unadjusted means, so it is consistent with the paper but does not reproduce the least-squares difference.
Limits of this record
- Total fatigue score direction: lower is better on the 4 to 16 scale. The abstract prints the interval as -0.10 to 0.26 around -0.07; WPF reproduces it as printed.
- The published figure and table locations in the full text (PMC10382259) were not read in this pass.
- The trial was stopped after the double-blind part missed its primary endpoints. A post hoc genotype analysis exists (PMID 39574155) and is not part of this result.
Versioned record: /api/research/journey/elamipretide?version=1.0.0&resultId=mmpower-3-6mwt-24w